This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Accurin Kinase Inhibitor (Amgen)
Drug Names(s): Accurin
The specific kinase target(s) have not been released by the companies, but in general, BIND Therapeutics develops nanoparticle encapsulated drugs with targeting agents on the particle surface to direct drugs to specific cells.
BioMedTracker will update the drug and target when more information is released from the companies.
BIND and Amgen
In January 2013, BIND announced that it entered into a global collaboration agreement with Amgen to develop and commercialize a kinase inhibitor nanomedicine for treating a range of solid tumors. Under the terms of the agreement, Amgen will have the exclusive right to pursue development and commercialization of the Accurin kinase inhibitor against solid tumor targets to be selected by Amgen. Both companies will work together on preclinical development and Amgen will assume responsibility for future development and commercialization. BIND could receive up-front and development milestone payments totaling $46.5 million, and BIND could receive up to an additional $134 million in regulatory and sales milestone payments for the first therapeutic indication and is eligible for additional payments. BIND will receive tiered royalties on potential future sales.
In December 2013, BIND announced that it amended its development and commercialization collaboration...See full deal structure in Biomedtracker
Accurin Kinase Inhibitor (Amgen) News
Additional information available to subscribers only: